Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 123-135 , February 2012

Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes

  • F. Efficace

      Affiliations

    • Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center and Health Outcomes Research Unit, Via Benevento 6, 00161 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 441 639831; fax: +39 06 4402516.
    • ,
  • K. Cocks

      Affiliations

    • University of Leeds, Clinical Trials Research Unit, Leeds, UK
    • ,
  • M. Breccia

      Affiliations

    • University of Rome “Sapienza”, Department of Hematology, Rome, Italy
    • ,
  • M. Sprangers

      Affiliations

    • University of Amsterdam, Academic Medical Center, Department of Medical Psychology, Amsterdam, The Netherlands
    • ,
  • C.A. Meyers

      Affiliations

    • The University of Texas, M.D. Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX, USA
    • ,
  • M. Vignetti

      Affiliations

    • University of Rome “Sapienza”, Department of Hematology, Rome, Italy
    • ,
  • M. Baccarani

      Affiliations

    • University of Bologna, S. Orsola-Malpighi Hospital, Department of Hematology and Oncology, Bologna, Italy
    • ,
  • F. Mandelli

      Affiliations

    • Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center and Health Outcomes Research Unit, Via Benevento 6, 00161 Rome, Italy
    • ,
  • GIMEMA and EORTC Quality of Life Group

,Accepted 22 February 2011.

References 

  1. Hehlmann R, Hochhaus A, Baccarani M on behalf of the European LeukemiaNet. Chronic myeloid leukaemia. Lancet. 2007;370:342–350
  2. Deininger M. Chronic myeloid leukaemia: an historical perspective. Hematology Am Soc Hematol Educ Program. 2008;418
  3. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukaemia: past, present and future. Am J Hematol. 2009;84:287–293
  4. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
  5. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts). 2009;114;[abstract 1462]
  6. Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(June (24)):2251–2259
  7. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051
  8. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(September (6)):1809–1820
  9. Dalziel K, Round A, Stein K, et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: a systematic review and economic analysis. Health Technol Assess. 2004;8(28):iii1–120
  10. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12:608–616
  11. Osoba D, Tannock IF, Ernst DS, et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654–1663
  12. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma. 2005;46:1709–1714
  13. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer. 2008;44:1497–1506
  14. Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev. 2004;30:103–117
  15. ASCO . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol. 1996;14:671–679
  16. National Cancer Institute: The NCI Strategic Plan for Leading the Nation. To eliminate the suffering and death due to cancer. National Institutes of Health Publication No. 06-5773. http://strategicplan.nci.nih.gov/pdf/nci_2007_strategic_plan.pdf.
  17. US Food and Drug Administration . Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration; December 2009;http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
  18. Bottomley A, Therasse P. Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol. 2002;3:620–628
  19. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai S. Health-related quality of life in non small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol. 2003;21:2982–2992
  20. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials. Eur J Cancer. 2004;40:187–197
  21. Efficace F, Bottomley A, Van Andel G. Health-related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer. 2003;97:377–388
  22. Efficace F, Novik A, Vignetti M, Mandelli F, Cleeland CS. Health-related quality of life and symptom assessment in clinical research of patients with haematological malignancies: where are we now and where do we go from here?. Haematologica. 2007;92:1596–1598
  23. Efficace F, Bottomley A, Osoba D, et al. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision-making?. J Clin Oncol. 2003;21:3502–3511
  24. Winters ZE, Benson JR, Pusic AL. A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life. Ann Surg. 2010;252:929–942
  25. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24(July (19)):3178–3186
  26. Cocks K, King MT, Velikova G, et al. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44:1793–1798
  27. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon Alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27(June (18)):2916–2923
  28. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937–944
  29. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  30. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med. 1998;17:517–532
  31. Fairclough DL. Methods of anaysis for longitudinal studies of health-related quality of life. In:  Staquet MJ,  Hays RD,  Fayers PM editor. Quality of life assessment in clinical trials: methods and practice. Oxford, England: Oxford University Press; 1998;p. 227–247
  32. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144
  33. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995;45(May (5)):947–950
  34. Bertero C, Eriksson BE, Ek AC. A substantive theory of quality of life of adults with chronic leukaemia. Int J Nurs Stud. 1997;34(1):9–16
  35. Stalfelt AM, Zettervall O. Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon. Leuk Res. 1997;21(8):775–783
  36. Homewood J, Watson M, Richards SM, Halsey J, Shepherd PC. Treatment of CML using IFN-alpha: impact on quality of life. Hematol J. 2003;4(4):253–262
  37. Kluin-Nelemans HC, Buck G, Le Cessie S, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood. 2004;103(12):4408–4415
  38. Scheibel RS, Valentine AD, O’Brien S, Meyers CA. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 2004;16(Spring (2)):185–191
  39. Molassiotis A, Morris PJ. The meaning of quality of life and the effects of unrelated donor bone marrow transplants for chronic myeloid leukemia in adult long-term survivors. Cancer Nurs. 1998;21(3):205–211
  40. Molassiotis A, Morris PJ. Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation. Cancer Nurs. 1999;22(5):340–349
  41. Kiss TL, Abdolell M, Jamal N, et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol. 2002;20(9):2334–2343
  42. Chang G, Orav EJ, Tong MY, Antin JH. Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics. 2004;45(5):378–385
  43. Chang G, Orav EJ, McNamara T, Tong MY, Antin JH. Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome. Cancer. 2004;101(4):782–789
  44. Hayden PJ, Keogh F, Ni CM, et al. A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase. Bone Marrow Transplant. 2004;34(6):545–556
  45. Chang G, Orav EJ, McNamara TK, Tong MY, Antin JH. Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics. 2005;46(1):34–40
  46. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol. 2003;21(11):2138–2146
  47. Noens L, Van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–5411
  48. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  49. Derogatis LR. The Psychosocial Adjustment to Illness Scale. J Psychosom Res. 1986;30:77–91
  50. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–370
  51. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–483
  52. Baker F, Curbow B, Wingard JR. Development of the satisfaction with life domains scale for cancer. J Psychosoc Oncol. 1992;10:75–90
  53. Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant. 1997;19:1129–1136
  54. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index—Cancer: development and validation. J Clin Oncology. 1984;2:472–483
  55. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford Press; 1979;
  56. Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM) a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004;13(February (1)):137–154
  57. The EuroQol Group . EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208
  58. Ware JE, Kosinski M, Dewey JE, Gandek B. How to score and interpret single-item health status measures: a manual for users of the SF-8 Health Survey. Lincoln, RI: QualityMetric Incorporated; 2001;
  59. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(July (1)):7–19
  60. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(January (3)):424–430
  61. Hehlmann R, Jung-Munkwitz S, Lauseker M, et al. Randomized comparison of imatinib 800mg vs imatinib 400mg±IFN in newly diagnosed BCR/ABL positive chronic phase CML: analysis of molecular remission at 12 months. Blood. 2009;114(Suppl.):143–144
  62. Baccarani M, Druker BJ, Cortes-Franco J, et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts). 2009;114;[abstract 337]
  63. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2007;18:775–781
  64. Bottomley A, Flechtner H, Efficace F, et al. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer. 2005;41(August (12)):1697–1709
  65. Sprangers MA, Moinpour CM, Moynihan TJ, et al. Assessing meaningful change in quality of life over time: a users’ guide for clinicians. Mayo Clin Proc. 2002;77:561–571
  66. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109
  67. Williams LA, Ault P, Wang S, et al. The symptom burden of chronic myelogenous leukemia (CML). Blood (ASH Annual Meeting Abstracts). 2008;112:[abstract 2408]
  68. Coons SJ, Gwaltney CJ, Hays RD, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health. 2009;12(June (4)):419–429
  69. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health related quality of life—a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209–238
  70. Staquet M, Berzon R, Osoba D, et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5:496–502
  71. Gotay CC, Korn EL, McCabe MS, et al. Building quality of life assessment into cancer treatment studies. Oncology (Huntingt). 1992;6:25–28
  72. Gotay CC, Korn EL, McCabe MS, et al. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst. 1992;84:575–579
  73. Fayers PM, Hopwood P, Harvey A, et al. Quality of life assessment in clinical trials—guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience, MRC Cancer Trials Office. Eur J Cancer. 1997;33:20–28
  74. Haes de J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials – the EORTC model. Eur J Cancer. 2000;36:821–825
  75. Efficace F, Sprangers M. Designing and interpreting quality-of-life and other patient-reported outcomes in clinical trials. In: Education program for the 14th congress of the European Hematology Association (EHA). Berlin, Germany: Educational Book; 2009;p. 89–95
  76. Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer. 2011;117:688–697
  77. Wang XS, Cleeland CS, Mendoza TR, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010;102(May (10)):732–738
  78. Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol. 2010;148(February (3)):373–385

☆ Presented at the 52nd Annual Meeting of the American Society of Hematology (ASH), December 4–7, 2010, Orlando, FL, USA.

PII: S1040-8428(11)00053-9

doi: 10.1016/j.critrevonc.2011.02.007

Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 123-135 , February 2012

Article Tools

* Image Usage & Resolution